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disease 
Nwe Ni Than, Philip N Newsome 
The Centre of Liver Research and NIHR Biomedical Research Unit in Liver Diseases, University of 
Birmingham and University Hospital Birmingham NHS Trust, UK 
 
Abstract 
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome 
and the incidence of which is rising rapidly due to the increasing epidemic of obesity in both adults 
and children. The initial accumulation of fat followed by subsequent inflammation is central to the 
development of liver damage, and is critically influenced by host factors including age, gender, 
presence of diabetes, genetic polymorphisms and more recently by the gut microbiome. An increasing 
body of data suggest that NAFLD is also an independent risk factor of cardiovascular disease, which 
remains the commonest cause of mortality in such patients. This review focusses on the pathogenesis 
of NAFLD, and the evolution of new approaches to the management and treatment of NAFLD. 
 
Keywords: Non-alcoholic fatty liver disease, pathogenesis, dyslipidaemia, insulin resistance, 
cardiovascular disease 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
2 
 
 
Table of Contents 
Introduction ............................................................................................................................................................ 3 
Epidemiology ......................................................................................................................................................... 3 
Natural history and pathogenesis of NAFLD ......................................................................................................... 4 
Two hit hypothesis: ............................................................................................................................................ 4 
Insulin resistance ................................................................................................................................................ 4 
Free fatty acids ................................................................................................................................................... 5 
Adipose tissue .................................................................................................................................................... 6 
Death and repair...................................................................................................................................................... 6 
Genetic polymorphisms .......................................................................................................................................... 7 
Gut-Liver axis and the microbiome ........................................................................................................................ 7 
NAFLD and cardiovascular risk ............................................................................................................................. 9 
Diagnosis .............................................................................................................................................................. 10 
Treatment .............................................................................................................................................................. 11 
Lifestyle management ...................................................................................................................................... 11 
Weight loss therapy using pharmacological agents .......................................................................................... 11 
Bariatric surgery ............................................................................................................................................... 12 
Pharmacological management .......................................................................................................................... 12 
Insulin sensitizers ......................................................................................................................................... 12 
Lipid lowering drugs .................................................................................................................................... 13 
Hypertension ................................................................................................................................................ 13 
Anti-oxidants and cytoprotective therapies .................................................................................................. 13 
Microbiomes ................................................................................................................................................ 14 
Liver transplantation ........................................................................................................................................ 14 
Conclusion ............................................................................................................................................................ 14 
Conflict of interest: .......................................................................................................................................... 14 
Disclosure ......................................................................................................................................................... 14 
Funding: ........................................................................................................................................................... 14 
References: ........................................................................................................................................................... 15 
Figure legends: ..................................................................................................................................................... 22 
Figure 1: Clinical progression of non-alcoholic fatty liver disease .................................................................. 22 
Figure 2: Pathogenesis of non-alcoholic fatty liver disease ............................................................................. 22 
Table 1: Summary of treatments studied for patients with Non-alcoholic fatty liver disease .......................... 23 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3 
 
Introduction  
Non-alcoholic fatty liver disease (NAFLD) is becoming an important public health concern due to the 
rising incidence of obesity in both children and adults. NAFLD, defined by the presence of hepatic 
steatosis (the presence of fat in liver parenchyma without inflammation) in the absence of excess 
alcohol consumption (less than 21 units in men and 14 units in women), is considered to represent the 
hepatic component of metabolic syndrome [1]. NAFLD represents a spectrum of disease, ranging 
from simple steatosis  to steatohepatitis (the presence of fat in liver parenchyma with inflammation, 
hepatocyte ballooning and lobular inflammation) through to fibrosis and cirrhosis [2]. Simple steatosis 
(SS) rarely progresses to advanced disease whereas in approximately 20% of patients with non-
alcoholic steatohepatitis (NASH), it progresses to fibrosis and cirrhosis over a 15 year time period [3].  
It is strongly associated with insulin resistance and other metabolic risk factors such as diabetes 
mellitus, central abdominal obesity and dyslipidaemia [4]. NAFLD is an independent risk factor for 
cardiovascular disease (CVD) and predicts future events, independently of other risk factors such as 
age,  gender, low density lipoprotein (LDL) cholesterol, smoking and other features of metabolic risk 
factors [5-7].  NAFLD is also associated with increased risk of all-cause mortality, contributed by 
liver related deaths as well as non-liver related causes such as malignancy,  diabetes and coronary 
artery disease [8].  
Epidemiology  
The prevalence of NAFLD in normal weight individuals without the presence of metabolic risk 
factors is reported to be around 16% [9] rising to 43-60% in patients with diabetes [10, 11], 91% in 
obese patients undergoing bariatric surgery [12], and up to 90% in patients with hyperlipidaemia [4, 
13]. The prevalence of NAFLD also increases with age from less than 20% under the age of 20 to 
more than 40% in over the age of 60 [6] and indeed  older age has been shown to be an independent 
risk factor for hepatic steatosis and progression to fibrosis and cirrhosis [14]. The male gender has 
been regarded as a risk factor for progression to NASH and fibrosis [14]. Although earlier studies 
suggested that ethnicity impacts on the prevalence of NAFLD [15], subsequent studies did not 
confirm this on multi-variant analysis [16]. Intriguingly though the link between insulin resistance 
(IR) [measured by homeostasis model assessment-estimated insulin resistance (HOMA-IR)] and the 
risk of NASH is seemingly different between Latino and non-Latino individuals [16].  
Mortality is increased in patients with steatohepatitis and advanced fibrosis but not in patients without 
evidence of steatohepatitis and fibrosis (known as bland steatosis). A long term follow up study of 
129 patients with biopsy proven NAFLD showed that mortality was not increased in patients with 
simple steatosis [17],but increased in patients with NASH. The mortality was related mainly to 
cardiovascular disease although liver related deaths were more common in patients with NASH 
cirrhosis [17]. A recent systematic review of 221 patients with biopsy proven NASH showed that 
patient’s age and the degree of inflammation on initial liver biopsy were independent predictors of 
progression to advanced fibrosis whilst factors such as diabetes, hypertension and obesity were not 
statistically significant predictors [18]. These findings supported that the presence of advanced 
fibrosis was associated with increased overall mortality [19] , most likely from cardiovascular events 
[19].  
Hamabe et al demonstrated in a retrospective study over a 10 year period that smoking was an 
independent risk factor for NAFLD irrespective of the presence of other metabolic risk factors [20]. 
Notably, the rate of development of NAFLD was similar in those individuals that stopped smoking to 
those that carried on, perhaps related to subsequent weight gain in individuals after cessation of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
4 
 
smoking [20]. Modest alcohol consumption (one alcoholic beverage per day) had not been 
demonstrated to increase the prevalence of NAFLD, and in the case of modest wine consumption it 
would appear to reduce the incidence [21].  
Natural history and pathogenesis of NAFLD 
The natural history and the pathogenesis of NAFLD is not clearly well described. In NAFLD, simple 
steatosis is regarded as the presence of fat in <5 % of hepatocytes [22] and in about 20-25% of cases, 
it progresses to NASH and of these patients with NASH, 20% will develop fibrosis and subsequently 
cirrhosis [3]. The mechanisms involved in the progression of steatosis to NASH are complex and not 
completely understood although increased visceral adiposity and insulin resistance (IR) with increased 
free fatty acids (FFA) release might play a role in the development of liver steatosis [22]. In healthy 
subjects, insulin stimulates hepatic as well as peripheral glucose uptake and suppress hepatic glucose 
production [23] whereas in the fasting state, the liver becomes the major site of glucose production as 
mediated by gluconeogenesis and glycogenolysis [2, 24]. In patients with IR, hepatic auto- regulation 
is disrupted and therefore, both gluconeogenesis and glycogenolysis are increased resulting in the 
development of hyperglycaemia [13]. The mechanism of the liver injury in NAFLD is currently 
thought to be a ‘multiple hit process’ involving IR, oxidative stress, apoptosis and perturbations of 
adipokines levels [25].   
 
Two hit hypothesis:  
The current model of ‘two hit hypothesis in NAFD’ was proposed in 1998 by Day et al [26]. The first 
hit reflects the accumulation of triglycerides (TG) and FFA in hepatocytes which is a consequence of 
IR, enhanced dietary influx and increased hepatic lipogenesis [26]. The second hit involves lipid 
peroxidation, mitochondrial dysfunction and inflammation which results in hepatocyte damage and 
development of liver fibrosis [26]. Activation of pro-inflammatory pathway is mediated by cytokine 
and pattern recognition receptors, including toll like receptors and these pathways emerge on two 
main intracellular signalling pathways, known as nuclear factor-κβ (NF- κβ) and c-Jun N-terminal 
kinase (JNK)[27, 28]. NF- κβ activation is reported in NASH and can lead to increased transcription 
of many pro-inflammatory genes, whereas JNK causes IR via direct phosphorylation and degradation 
of insulin receptor substrate 1 (IRS1), reducing the intracellular signalling pathway downstream the 
insulin receptor [27]. Lipid peroxidation can promote stellate cell proliferation contributing to 
fibrogenesis [29], whereas reactive oxygen species (ROS) induce cytokines release from hepatocytes 
that lead to the initiation of various immune mediated mechanisms contributing to further liver cell 
injury. The combination of hyperinsulinaemia, hepatic iron and lipid peroxidation induce oxidative 
stress [15], which can cause mitochondrial dysfunction in NASH and contribute to TG accumulation 
and eventually cell necrosis [11].  
Insulin resistance  
Patients with NAFLD have reduced insulin sensitivity not only in muscle but also in liver and adipose 
tissue [30], which play a major role in the pathogenesis of NAFLD. Due to IR, the adipose tissue 
becomes resistant to the anti-lipolytic effect of the insulin and results in peripheral lipolysis which 
causes an increase delivery of FFA to the liver as well as driving de novo lipogenesis (DNL) [6, 15]. 
In addition, lipid overload in pancreatic-B cells leads to dysregulated insulin secretion and changes in 
the expression of peroxisome proliferator-activated receptor-α (PPAR-α), glucokinase, the glucose 
transporter-2 (GLUT 2), pre-pro-insulin and pancreatix duodenal homeoboc-1 (PDX-1), which can 
lead to IR as a result of FFA- induced B-cell apoptosis [12].   
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A study on liver insulin knock out mice (LIKO) showed that on a standard chow diet, the mice have a 
proatherogenic lipid profile with low high density lipoprotein (HDL) cholesterol and very low density 
lipoprotein (VLDL) particles that are mainly enriched in cholesterol, although in the case of normal 
mice, VLDL is mainly composed of TG [31]. Within 12 weeks on an atherogenic diet (15% dairy fat, 
1% cholesterol, 0.5% cholic acid), the mice showed marked hypercholesterolemia and all of LIKO 
mice developed severe atherosclerosis [31]. Therefore, it has been suggested that IR at the level of 
liver is sufficient enough to produce the dyslipidaemia and increased the risk of atherosclerosis [32].  
Free fatty acids  
De novo lipogenesis (DNL) is an integrated metabolic pathway consisting of glycolysis (conversion 
of glucose to acetyl-CoA); biosynthesis of saturated fatty acids followed by desaturation, and the 
formation of TG and this pathway mainly takes place in adipose tissue and liver. Dysregulation of 
DNL is observed in patients with obesity, metabolic syndrome or NAFLD. DNL is up-regulated after 
a high carbohydrate and low fat diet leading to an increase in blood triacylglycerol levels that leads to 
an increase in the synthesis and secretion of VLDL in the liver and subsequently hepatic 
hypertriglyceridemia leading to steatosis [33]. Fat accumulates in the liver due to excessive intake of 
dietary FFAs and increased influx of FFA into the liver due to peripheral IR and increased hepatic 
DNL [37]. It has been demonstrated that around 26% of FFAs in the liver derived from hepatic DNL 
in individuals with NAFLD [38] with the remaining TG content being derived from lipolysis of 
adipose tissue store (59%) and from diet (15%) [38]. Although the exact underlying mechanism is not 
completely understood, it has been suggested that hepatic IR can be both a cause and/or a 
consequence of steatosis in the liver. Chronic hyperinsulinaemia, as found in NAFLD, promotes 
hepatic DNL through an up-regulation of lipogenic transcription factors [39, 40].  
A study [33] has demonstrated successfully that both serum concentration of carbomoyl phosphate 
synthase 1 (CPS1) and glucose regulated protein (GRP78) has decreased gradually in subjects from 
SS to NASH. GRP78 is immunoglobulin binding protein and is a central regulator of endoplasmic 
reticulum (ER) function and crucial for cell survival [34]. GRP78 inhibit both insulin dependent and 
ER-stress dependent sterol regulatory element-binding protein 1c (SREBP-1c) proteocleavage that 
plays an important role in DNL [34]. SREBP-1c regulates genes required for glucose metabolism, 
fatty acid and lipid production and its activity is regulated by insulin [35].  
Recent rodent studies demonstrated that in obesity, DNL is down regulated in white adipose tissue 
(WAT) and that its selective restoration in WAT reverts obesity-dependent IR [34, 35]. Human 
studies demonstrate similar findings; DNL enzymes are markedly suppressed in WAT of obese 
subjects, as is the glucose transporter type 4 (GLUT-4) [33]. This suppression is closely linked to 
impaired metabolic control and can be reversed by weight loss through bariatric intervention. This 
suggests that the level of DNL or its relevant products such as monounsaturated fatty acids in WAT is 
an important determinant of systemic IR and subsequent metabolic disease [33]. In contrast to WAT, 
DNL in the liver has been found to be upregulated in rodent and human obesity where it is believed to 
promote lipotoxicity, IR, atherogenic dyslipidaemia and NAFLD [36]. Based on this association 
between hepatic DNL and the metabolic syndrome, it is believed that inhibition of DNL may be a 
viable approach to treating obesity-related disorders such as type 2 diabetes (T2D) [37].  
The mechanisms of lipotoxicity as consequence of ectopic fat accumulation in the liver are poorly 
described. When the energy expenditure is less than energy intake, there is abundance of FFA 
resulting in overspill which are subsequently stored in muscle and liver as ectopic fat [38]. Lipid 
overload can also be found in other organs such as heart, muscle, pancreas and arterial wall where it is 
stored ectopically [13, 39]. Adipose tissues can store large amounts of excess FFA and when the 
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limited storage is exceeded, cell dysfunction or death will result, known as lipotoxicity [39]. 
Mechanisms of lipotoxicity involve apoptosis, decreased cardiolipin content, increased membrane 
permeability and cytochrome release in mitochondria, nuclear factor-kappa beta (NF-κβ) activation 
and oxidative stress [39, 40]. Previous studies from transgenic mice with over expression of 
lipoprotein lipase lead to lipid accumulation in the liver and in muscle leading organ specific IR [41, 
42]. In NAFLD, the accumulation of hepatic fat is believed to be the consequence of an imbalance 
between the uptake/production of fat in the liver and its subsequent secretion or metabolism [36].  
Kupffer cells (KC) constitute the largest cellular component of the reticuloendothelial system, 
representing 80%–90% of all tissue macrophages in the body [43] and about 10% of the resting total 
liver cell population. They are located in the liver sinusoids and can migrate into the space of Disse 
where they orchestrate cross-talk between various resident and recruited cells of the liver [44]. 
Hepatic steatosis and inflammation is also mediated by KC through the Toll-like receptors (TLR), 
mainly TLR-3 and TLR-4 as well as scavenger receptor pathway, mediating production of cytokines 
such as TNF-α and Interleukins-15 (IL-15) and IL-1 β [45, 46]. Animal study showed that the effect 
of KC on liver TG are medicated partially by IL-1 β which suppresses PPAR-α which is a gene 
involved in fatty acid oxidation [46]. It has also been shown that KC in NAFLD have a defective 
phagocytic function which may result in an impaired clearance of toxic substances, such as endotoxin, 
leading to hepatocyte damage [47], as supported by a study showing that the numbers of hepatic 
CD68+KC correlate with histological severity in patients with NAFLD [48].  
Adipose tissue 
Adipose tissue is the major source of FFA and responsible for 60% of TG accumulation. Previous 
studies had suggested that obese individuals often have enlarged adipocytes due to lipid overload. 
Excess lipid contents spill over from the incompetent and dysfunctional adipose tissue lead to ectopic 
lipid deposition in organs such as liver and muscle [48]. Moreover,  patients with central obesity have 
large amounts of visceral adipose tissue (VAT) which is defined as intra-abdominal fat bounded by 
parietal peritoneum or transversalis fascia and it is a major source of FFA, hormones, cytokines such 
as IL-6, tumour necrosis factor (TNF)-α, plasminogen activator inhibitor-1 (PAI-1), leptin, and 
adipokines [49]. These factors are secreted into the circulation and frequently taken up by the liver, 
with the peripheral FFA flux derived from VAT being the most notable example [39] . This flux in 
particular is a major determinant of accumulation of hepatic and lipoprotein fat in NAFLD [39]. Waist 
circumference is highly correlated with VAT in both genders and is used as a clinical marker for 
abdominal obesity and found to be better predictor than body mass index (BMI) [25]. 
 
Adiponectin is a protein that acts a protective adipokine by inhibiting liver gluconeogenesis and 
suppressing lipogenesis [25], an effect mediated mainly through activation of AMP mediated protein 
kinase  (AMPK) and PPAR-α, thus stimulating fatty acid oxidation in liver and muscle [13]. 
Adiponectin levels also correlate inversely with plasma TG and positively with HDL-cholesterol and 
low LDL- cholesterol levels [13]. Patients with NAFLD have lower adiponectin concentration than 
normal subjects despite higher lipolysis and fatty acid concentrations [13]. Therefore, low adiponectin 
in NAFLD enhances FFA overload and lipid oxidation and consequently play a role in progression 
from steatosis to NASH [7]. 
Death and repair 
Hepatocyte apoptosis plays a critical role in liver injury and the development of NASH [50]. Soluble 
Fas, a death receptor membrane of the TNF family appears to have an important role in hepatocyte 
apoptosis. The accumulation of FFA in hepatocytes triggered upregulation of Fas ligands and 
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activation of Fas receptors which results in apoptosis [51]. In addition, effector caspases (mainly 
caspase-3) cleave various substrates inside the cell including cytokeratin 18 (CK-18), which is a major 
intermediate filament protein in the liver, resulting in apoptosis [52]. Fragments of CK-18 are 
detectable in the bloodstream by ELISA and it has a promising aspect as a diagnostic tool in near 
future.  
Hedgehog (Hh) signalling has been implicated in hepatic tissue repair resulting in its study in NAFLD 
to establish whether aberrant or prolonged signalling may impact on disease progression in NAFLD 
[14]. Notably, the level of Hh activity seems to be proportional to the severity and duration of liver 
disease in both rodents and humans [14]. Macrophage infiltration is also seen in patient with NASH 
[24], and monocyte chemoattractant protein (MCP)-1 is also an important factor in NASH as it can 
potentially mediates the progression of disease by causing persistent inflammation as a result of 
infiltration of leucocytes into the liver [24]. 
Genetic polymorphisms 
Two independent genome-wide association studies linked the common rs738409 polymorphism of 
palatin-like phospholipase domain-containing 3 gene (PNPLA3) with hepatic fat content and liver 
enzyme levels [53, 54]. This single variant (rs738409) substitutes cytosine to guanine that changes 
codon 148 of the protein from isoleucine to methionine [55]. The protein encoding PNPLA3, known 
as adiponutrin is particularly associated with increased hepatocyte fat content [14].  In humans, 
PNPLA3 is mainly expressed in intracellular membrane fractions in hepatocytes, and is induced in the 
liver after feeding and during IR [53]; the G allele has been shown to be associated with increased risk 
of hepatic TG accumulation ad hence NAFLD [14]. The normal genotype is CC allele and the most 
common found in NAFLD is CG allele and GG allele which have the worse outcome with rapid 
progression to fibrosis and cirrhosis [56, 57]. Since the discovery of the association between the 
PNPLA3 mutation with steatosis and steatohepatitis, several additional single nucleotide 
polymorphisms (SNPs) have been identified in individuals with NASH. Genome wide studies looking 
at non-Hispanic, Caucasian women with biopsy proven NAFLD [58] showed that non-alcoholic 
steatosis (NAS) was significantly associated with rs2645424 on chromosome 8 in the farnesyl 
diphosphate farnesyl transferase-1 gene (FDFT-1), which is a key regulator of cholesterol 
biosynthesis. This pilot study also showed that the degree of fibrosis was strongly correlated with 
SNP rs343062 on chromosome 7 although the exact function of this SNP is unknown. Three SNPs 
were associated with the lobular inflammation phenotype: SNP rs1227756 on chromosome 10 in the 
COL13A1 (and collagen, type XIII, α 1) gene, rs6591182 on chromosome 11, and rs887304 on 
chromosome 12 in the EF-hand calcium binding domain 4B(EFCAB4B) gene. 
 
Another common gene variant, glucokinase regulatory protein (GCKR) has been studied extensively. 
GCKR regulates glucokinase, a phosphorylating enzyme that responsible for hepatic glucose 
metabolism and activates hepatic lipogenesis [59]. Polymorphism of this particular gene (rs780094 
and rs1260326) was associated with increased risk of type 2 diabetes, especially in Asian population 
[60].  
Gut-Liver axis and the microbiome 
The human gastrointestinal tract predominantly consists of anaerobic bacteria and harbors three 
dominating bacterial phyla: the gram-positive Firmicutes and Actinobacteria, and the gram-negative 
Bacteroidetes [61]. In adults, almost 60%–80% of the gut microbiota consists of Firmicutes and 
approximately 20%–40% are Bacteroidetes [62]. In healthy host, the gut microbiota plays many 
important roles by the secretion of bioactive metabolites, protect against pathogens by maintaining 
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immunity, perform digestion of complex carbohydrates, synthesize vitamins and store fat.  The gut 
epithelium acts as natural barrier and keeps bacteria, their byproducts and other harmful elements at 
bay due to the presence of tight junctions and specialised intracellular structures.  
 
The intestinal mucosa serves as a defence barrier that helps prevent the entrance and the systemic 
spread of bacteria and endotoxins, most of which are lipopolysaccharides (LPS) from the cell walls of 
gram-negative bacteria [63]. However, under certain conditions, this intestinal barrier fails, resulting 
in bacterial and endotoxin invasion into the gastrointestinal (GI) tract, after which the pathogens reach 
systemic organs and tissues; this process is termed bacterial translocation [63]. These microbial 
products exert pro-inflammatory actions mediated through TLRs [63]. TLRs detect the pathogens 
enabling  the host to regulate immune responses evident on the surfaces of hepatocytes, KC and 
hepatic stellate cells [63]. As explained by Baldwin, the activation of TLR4 by LPS triggers an 
essential intracellular inflammatory cascade, includes stress-activated and mitogen-activated protein 
kinases, c-Jun-N- terminal kinase, p38 and the NFκβ pathway [64]. Therefore, TLR4 has a prominent 
role in promoting inflammation and injury in conditions such as alcoholic liver disease and NASH 
[63]. Increasing data have underlined the potentially critical role of the microbiome in the 
pathogenesis of NAFLD [65]. Different animal mouse models showed that inflammasome-deficiency-
associated changes in the configuration of the gut microbiota are associated with increased hepatic 
steatosis and inflammation through the influx of TLR-4 and TLR-9 agonists into the portal 
circulation, leading to the increased expression of TNF-α, which drives NASH progression [65]. 
Defective NLR related protein (NLPR)-2 and NLPR-6 inflammasomes altered the interactions 
between the host and the gut microbiota and they negatively regulate NAFLD/NASH progression as 
well as the many aspects of metabolic syndrome via modulation of the gut microbiota [65].   
 
The liver continuously receives blood from the gut through the portal system and therefore, subjected 
to translocation of bacteria, bacterial products, endotoxin or secreted cytokines present in the gut. 
Normally, endotoxaemia in the portal circulation is rapidly cleared by the liver’s endothelial system, 
mainly KC [63]. However, in the case of liver disease, the endotoxaemic burden is higher and the 
mechanisms to clear these endotoxins are poorer resulting in ongoing inflammation. Miele et al 
demonstrated that patients with NAFLD have increased gut permeability, possibility related to small 
bacterial overgrowth (SIBO) resulting in tight junction disruption, which may impact on NAFLD 
progression [31]. Most of these studies were performed on animal models and hence, more research is 
needed in this area of field to understand how such mechanisms apply in the clinical setting.  
 
A recently published prospective, cross-sectional study identified important differences in intestinal 
microbiota (IM) in patients with biopsy proven NAFLD (simple steatosis/SS or NASH) and healthy 
controls [66]. Patients with NASH had a lower percentage of Bacteroidetes and a higher percentage of 
Coccoides compared to both SS and healthy controls with no differences seen in the remaining 
microorganisms. Differences in levels of faecal Bacteroidetes still remained after adjusting for BMI 
and dietary fat intake between the groups suggesting that IM may play a role in the pathogenesis of 
NAFLD.  
 
Recent study [67] determined the effect of gut microflora alterations in a murine model of high-fat-
diet (HFD) induced NAFLD . The study showed that when HFD-fed mice were treated with 
antibiotics, there was a significant increase in conjugated bile acid metabolites, which inhibited 
intestinal farnesoid X receptor (FXR) signalling and as a result, there was a reduction of hepatic TG 
accumulation. This was noted to be due to modulation of gut microflora by reduction of ceramide 
levels in the serum and ileum resulting in down regulation of hepatic SREPBP1C and decreased DNL.  
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This particular study suggested that there might be a potential therapeutic target for NAFLD treatment 
by inhibiting intestinal FXR.  
NAFLD and cardiovascular risk  
The pathophysiological mechanisms that link NAFLD with coronary heart disease (CHD), myocardial 
dysfunction/hypertrophy, aortic valve sclerosis (AVS) and cardiac arrhythmias are incompletely 
understood [68]. The complex interactions including IR and visceral obesity make it extremely 
difficult to dissect out the precise causal relationships responsible for the increased risk of CHD and 
other cardiac and arrhythmic complications observed in patients with NAFLD [68]. The concept so 
far was that in patients with NASH, there was an increase in systemic and hepatic IR which in turn 
caused the accumulation of atherogenic dyslipidameia, characterised by high TG, low HDL and high 
VLDL. In NASH, there seemed to be increased production of many pro-inflammatory markers such 
as uric acid and C-reactive protein (CRP) [69], IL-6, TNF-α as well as pro fibrogenic markers such as 
tumor growth factor-β, endothelin 1 and insulin like growth factor-1 which can lead to CHD [70]. A 
observational study showed that high CRP levels are higher in biopsy proven NASH compared to SS 
although CRP levels do not reflect the degree between inflammation and fibrosis [71].  
Epidemiological studies performed in United States and Japan showed that NAFLD is associated with 
increased risk of cardiovascular disease (CVD) and is a predictor of CVD independent of the presence 
of other metabolic syndrome risk factors such as hypertension, diabetes, dyslipidaemia, obesity and 
IR [21, 22].  The RISC (Relationship between Insulin Sensitivity and Cardiovascular disease) study 
showed that patients with NAFLD had an increased 10 year coronary heart disease risk score even 
when only considering those at perceived low risk patients (i.e. without diabetes or hypertension) 
[23]. The study also showed that subjects with NAFLD are more prone to early carotid atherosclerosis 
in the absence of co-existing metabolic syndrome risk factors [23].  
 
Recent phase II trials assessing coronary atherosclerotic plaque in patients with NAFLD have showed 
that such patients are more likely to have advanced high risk coronary plaque, independent of 
traditional cardiovascular risk factors as compared with patients without NAFLD [72].  In a recent 
large cohort study of biopsy proven NAFLD such patients had an increased risk of death from 
cardiovascular and liver related causes [73]. The worst prognosis was seen in patients with stage 3 or 
4 fibrosis at baseline, although surprisingly, in patients with high NAS score (between grade 5 and 8) 
with no fibrosis did not have increased mortality rate compared to the reference population [73]. This 
observation requires further confirmation in larger cohorts to exclude the possibility of a type 2 error. 
In another study of patients with a Framingham cardiovascular risk score ≥20%, the presence of 
advanced fibrosis was predictive of cardiovascular events [19].  A recent study suggests that 
progression of NAFLD and risk of cardiovascular disease may not be a shared pathway since the 
carriers of gene TM6SF2 E167K variant have lower serum VLDL and lower risk of cardiovascular 
disease compared to non-carriers. However, they have more advanced fatty liver disease with severe 
steatosis, necro-inflammation, ballooning and fibrosis [74].  
 
Previous studies had shown that carotid-artery intimal medial thickness is related to the severity of 
NAFLD histology, independently of other cardio metabolic risk factors [75, 76]. A retrospective study 
showed that NAFLD, assessed by either CT or ultrasonography, was significantly associated with 
increased coronary artery calcification (CAC) score (i.e., CAC score > 100), independently of 
traditional CVD risk factors [77]. The concurrent finding of abdominal obesity which is significantly 
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correlated with left ventricular dysfunction also increases all-cause mortality [14]. The hepatic 
production of PAI-1 is also elevated in NAFLD patients, which is a known risk factor for CVD [2].  
A range of other pro-inflammatory molecules which are secreted by the liver (uric acid, CRP and 
homocysteine concentration) in response to oxidative stress may further impact on the associated 
cardiovascular risk in NAFLD [11]. Increased CRP promotes inflammation and accelerates 
atherosclerosis by increasing expression of PAI-1 and adhesion molecules in endothelial cells, 
inhibiting nitric oxide formation and increasing LDL uptake into macrophages [5]. IL-6 and TNFα are 
the major stimuli responsible for increased hepatic production of CRP, fibrinogen and other acute-
phase proteins [2, 10]. Uric acid, as result of increase in urea, was regulated by decrease in CPS 1 (a 
ligase enzyme located in the mitochondria) and it has been shown to erect pro-inflammatory and pro-
oxidant effect both on adipose tissue and vascular smooth muscles [78, 79]. Uric acid may also 
contribute to IR by inducing local adipose tissue inflammation, which may cause reduction in 
production of adiponectin [80].  
 
Dyslipidaemia when associated with NAFLD tend to be pro-atherogenic in nature [81]. The 
characteristic findings are increased plasma concentrations of VLDL, TG and decreased HDL 
cholesterol [7],  is found in up to 80% of cases of NAFLD [13].  Lipoprotein is important part of 
underlying mechanistic action in dyslipidaemia associated with NAFLD. Lipoprotein helped with 
delivery of cholesterol and TG from the liver and intestine to muscle and fat tissue and that action is 
mediated either by chylomicron and VLDL particles that contain apolipoprotein (apo) B48 and 
apoB100 or in the case of cholesterol, it is indirectly by conversion of intermediate density 
lipoproteins (IDL) to LDL. The second function of lipoprotein is the transport of excess cholesterol 
from extra-hepatic tissue to the liver for the elimination via bile, which is mediated primarily by HDL 
particles. Both functions are altered in NAFLD. Individuals with NAFLD have reduced hepatic 
insulin sensitivity and glucose clearance despite having high circulating insulin levels which can 
contribute to dyslipidemia [13, 82]. Apolipoproteins are proteins that transport lipids in blood 
circulation. A recent study showed that Apo B/Apo A1 ratio are associated with the prevalence of 
NAFLD and was independent of obesity and other metabolic components and therefore, the ratio 
might be useful as a predictive marker for cardiovascular risk in NAFLD [83].  
 
IR has been regarded as one of the factors responsible for atherogenic dyslipidaemia, as it increases 
release of non-esterified fatty acids (NEFA) or FFA which stimulates hepatic TG output [7]. IR and 
increased lipid availability within the liver also inhibit apolipoprotein B degradation, stabilising the 
formation of more VLDL which contains highest amount of TG [7, 23]. Individuals with type 2 
diabetes and NAFLD have increased TG accumulation independent of their BMI [13], resulting in 
cytotoxicity due to increased ROS generation and mitochondrial dysfunction [84]. Subjects with 
NAFLD, despite high circulating insulin levels, have reduced hepatic insulin sensitivity, poor 
postprandial glucose clearance, increased FFA and TG concentrations. The treatment of dyslipidaemia 
plays a critical role in the overall management of these patients.  
Diagnosis 
NAFLD is commonly asymptomatic disease and often identified incidentally [85]. Clinicians should 
consider a diagnosis of NAFLD in patients with abnormal liver tests and the presence of one or more 
metabolic risk factors; indeed the likelihood of NAFLD increases proportionately with the number of 
metabolic syndrome factors present [86].  Whilst serum aspartate transaminase (AST) and alanine 
transaminase (ALT) levels  may be abnormal in the setting of NAFLD, they are often not, even when 
using more stringent cut-offs for the upper limit of normal [87]. Several studies had demonstrated that 
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ALT is a poor marker to predict advance fibrosis in NAFLD patients [88]. Ultrasound scan will show 
an echobright liver in patients with at least 30% steatosis with a sensitivity of 64% and sensitivity of 
85% rising to 90 to 100% [6]. Other modalities of identifying hepatic steatosis include the controlled 
attenuation parameter (CAP software on the Fibroscan system [89, 90] and magnetic resonance 
spectroscopy (MRS) which are left to be more sensitive and can also provide a quantitative 
assessment of statuses [91, 92]. For the non-invasive assessment of fibrosis in NAFLD, there are 
several scoring systems described which have broadly similar ability to identify those patients with 
little or significant liver fibrosis[93]. Variables common to many of them include the ratio of AST: 
ALT, age, BMI and impaired glucose tolerance. Other non-invasive tests for determination of liver 
fibrosis include serum European Liver Fibrosis (ELF) panel (combination of 3 serum markers: 
Hyaluronic acid, Pro-collagen III amino terminal peptide and Tissue inhibitor of metalloproteinase 1) 
and Fibro-test which have been reviewed in details in the literature [94]. Transient elastography such 
as the Fibroscan has been validated in NAFLD and is often used as an adjunctive non-invasive test to 
assess liver fibrosis in the outpatient setting. Currently, liver biopsy still represents the gold standard 
for the diagnosis and staging of NAFLD/NASH and is required as the primary end-point for later 
stage clinical trials [7, 95].  
Treatment 
Lifestyle management 
Lifestyle intervention with diet and exercise is still the mainstay in the management of patient with 
NAFLD.  Although lifestyle intervention when achieved is effective, it can be difficult to implement, 
and thus the aim should be gradual but consistent weight loss over 6 to 12 months [96]. Commonly 
individuals are recommended to restrict caloric intake by approximately 500-1000 kcal/day in 
conjunction with regular interactions with a dietician [97, 98]. Simple carbohydrates in the diet, in 
particular fructose, have been linked to NAFLD. Carbohydrate consumption affects glucose 
homeostasis and free fatty acids metabolism in the liver and hence carbohydrate-restricted diet also 
has been studied previously [99]. Several studies indicate that a reduction of between 7 to 10% of 
body weight is associated with a reduction in inflammation in the setting of NAFLD, and thus is set as 
a target [100]. Whilst exercise in isolation has not been proven to be effective, as part of dietary 
changes moderate intensity exercise such as brisk walking of 30-45 minutes per day can improve 
biochemical and histological aspects of NAFLD [100].  Recent retrospective data from 169 obese, 
middle-aged men who were enrolled in a 12-week weight reduction program through lifestyle 
modification consisting of dietary restriction plus aerobic exercise showed that moderate to vigorous 
physical activity (MVPA) ≥ 250 minutes per week led to significant decrease in VAT severity, lipid 
peroxidation and a significant increase in adiponectin levels compared to those who exercise less 
[101].  
 
Weight loss therapy using pharmacological agents 
Orlistat produces moderate weight loss by reducing the absorption of fat by 30 % by inhibition of  
gastric and pancreatic lipases [96].  However, recent studies indicate the effects of Orlistat in patients 
with NAFLD are modest and restricted only to those patients that achieved 9% weight loss with 
lifestyle intervention [102].  
Sibutramine is a serotonin and noradrenaline reuptake inhibitor that increases satiety and can lead to 
modest weight loss [103, 104] and in a 6 month treatment study of obese patients with NASH, it 
reduced body weight by 10%, improved insulin resistance and decreased transaminase levels [105]. 
However, sibutramine use was suspended due to its risk of cardiac related mortality [106].  
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Rimonabant, a cannabinoid receptor antagonist, was a promising agent that induced significant weight 
loss in association with improvements in insulin resistance and serum lipid and adiponectin levels, 
however it has been taken off the market in 2008 due to severe psychiatric side effects [107-110].  
Bariatric surgery 
Bariatric surgery, as indicated for weight loss, has been shown to reduce most of the histological 
features of NAFLD in several studies [111] as well as obesity associated T2DM and IR. NAFLD is 
not, as yet, a standalone indication for bariatric surgery although it is commonly factored into the 
decision making in the management of overweight patients.  Bariatric surgery increases insulin 
sensitivity in the liver, muscle and fat due to weight loss and hence, will improve overall metabolic 
health. Weight loss after bariatric surgery increases insulin sensitivity in liver, muscle and fat. Thus, it 
is well recognized that bariatric surgery can improve overall metabolic health, but it remains unclear 
how it improves insulin sensitivity.  
Pharmacological management 
Insulin sensitizers 
Given the important of IR in the pathogenesis of NAFLD, insulin sensitizers such as metformin and 
thiazolidinedione (TZDs), have been extensively studied in the treatment of NAFLD [4].  
 
Metformin: Metformin is a biguanide insulin sensitizer widely used in treatment of type 2 diabetes, 
whose major action is mediated through activation of AMPK [112]. This improves peripheral glucose 
intake, reduces hepatic gluconeogenesis and lipogenesis and also increases beta oxidation of FFA 
[113] . However, clinical studies in NAFLD have not demonstrated a consistent benefit in patients 
with NAFLD and thus its use is reserved for the management of patients with NAFLD and 
concomitant type 2 diabetes [114, 115].  
 
Thiazolidinediones (TZDs): TZDs are agonists for PPAR-gamma and their actions in NAFLD are 
probably indirect and in large part, relate to their effects on adipose tissue. Moreover, TZDs can also 
upregulate adiponectin and/or sitrulin in hepatocytes which modulate central hepatic metabolic 
regulators such as AMPK, Foxo1 (Forkhead box O1), LKB1 (Liver Kinase B1), NAD (Nicotinamide 
adenine dinucleotide), NADH (Reduced nicotinamide adenine dinucleotide), PGC-1α and PPAR-1α. 
These result in increased fatty acid oxidation and subsequently lead to reduction in hepatic fat 
accumulation [4], and indeed these therapeutic agents have been demonstrated to have potent benefits 
in pre-clinical models of NAFLD. However, clinical concerns remain about their effect on reducing 
renal excretion of sodium and intestinal ion transport, which results in raised plasma volume/fluid 
retention [116] and exacerbations of pre-existing heart failure [117]. TZDs also reduce hepatic 
steatosis and improve insulin sensitivity in muscle and liver by enhancing adipocyte insulin sensitivity 
and shifting ectopic lipid from muscle and the liver to subcutaneous adipose tissue [38].  
 
A study looking at a regimen of hypo-caloric diet (500kcal per day) plus pioglitazone versus hypo-
caloric diet and placebo in patients with T2DM and NAFLD showed that pioglitazone led to 
metabolic and histologic improvement in subjects with non-alcoholic steatohepatitis, although the 
sample size was small [118]. Whilst pioglitazone did not meet the primary end point in a large, multi-
centre randomised controlled trial (PIVENS - Pioglitazone or Vitamin E for NASH study), it did 
improve insulin sensitivity and clearance of steatohepatitis compared to placebo [119]. Indeed, meta-
analysis of clinical trials with Pioglitazone does demonstrate clinical benefit in NAFLD although the 
associated weight gain, peripheral oedema and other cautions have limited its use in clinical practice 
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[115]. Overall, the effects of TZDs on NAFLD are indirect and perhaps predominantly a result of 
reduction of fat deposition in the liver.  
 
 
Incretin based therapies: Incretins, a gut derived neuro endocrine hormones, are produced by the 
intestinal tract in response to food ingestion and they stimulate glucose dependent insulin release, 
decrease glucagon release [120] and prolong gastric emptying [121]. Consequently these drugs are 
licensed for the management of type 2 diabetes where they improve glycaemic control, increased 
insulin sensitivity and cause significant weight loss. Circulating glucagon like peptide-1 (GLP-1) has 
a half-life of about 1-2 minutes due to rapid degradation by the enzyme dipeptdyl peptidase-4 (DPP-4) 
and thus, GLP-1 receptor agonists with increased DPP-4 resistance (e.g., Liraglutide, Exenatide) [122-
125]and DPP-4 inhibitors (e.g., Sitagliptin, Saxagliptin) [126, 127] have been developed as therapies. 
These agents offer promise in NAFLD and on the basis of encouraging open-label studies controlled 
trials in NAFLD are underway [128].  
Lipid lowering drugs 
Statins, fibrates and omega-3 polyunsaturated fatty acids (PUFAs) are used to manage dyslipidaemia 
[4], which is commonly found in patients with NAFLD. There are no studies to support direct benefit 
of those drugs in NAFLD, but they will be important in reducing the concomitant cardiovascular risk.  
Hypertension  
Angiotensin II receptor blockers (AIIRB): AIIRB inhibit the proliferation of stellate cells, reducing 
inflammation and fibrosis, and although early clinical studies with Losartan and Telmisartan have 
suggested improvements in transaminases and histology in patients with NASH, larger trials have not 
yet been performed. [105].  
 
Anti-oxidants and cytoprotective therapies 
Vitamin E: Vitamin E, a fat soluble vitamin, has an anti-oxidant property and two recently published, 
large, randomized controlled trials, PIVENS and TONIC (Treatment of non-alcoholic fatty liver 
disease in children), assessed its effect on adult and paediatric NAFLD populations, respectively [119, 
129]. Vitamin E treatment met the primary end- point in both trials [119, 129] however, there remain 
concerns about the long term safety at the high dose used (400 IU/day) since it has been shown to 
increase all-cause mortality.    
 
Betaine: Betaine is a naturally occurring metabolite of choline and has been shown to increase S-
adenosylmethionine levels and reduce oxidative stress [130]. Unfortunately, when compared with 
placebo in a randomized controlled trial, Betaine failed to improve steatosis or other histological 
outcomes [131].  
 
Ursodeoxycholic acid (UDCA): UDCA is a hydrophilic bile acid with cytoprotective and antioxidant 
properties [105] . Two well-designed RCTs examining UDCA failed to show any significant 
histological improvements with UDCA alone in patients with biopsy-proven NASH [132, 133].  
 
Pentoxyphylline: Pentoxyphylline is a tumour necrosis factor alpha (TNFα) inhibitor which has been 
evaluated in NASH for its anti-inflammatory properties [105]. A meta-analysis of randomized, 
double-blinded, placebo-controlled trials showed that Pentoxyphylline could reduce the 
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aminotransferase activities and improve the histological parameters in NAFLD patients [134], but the 
results needs to be confirmed in larger studies.  
Microbiomes  
Probiotics have attracted interest given their possible ability to alter  the composition of Intestinal 
microbiota (IM) and the subsequent interaction with the immune system and gut epithelium [135]. 
Commercial probiotics commonly include lactic acid bacteria (Clostridium/Bacillus gram-positive 
bacteria and Actinomycetes gram-positive Bifidobacteria) and spore-forming bacteria (Clostridium-
Bacillus gram-positive bacteria) [135]. Several probiotic stain, mainly lactobacillus species, produce 
lactic acid and being acid resistant, they persist in the stomach longer than other bacteria which 
protect them against gastric non immunological barriers  such as acidity and mucosal barriers.  
 
A recent meta-analysis of 134 NAFLD/NASH patients from 14 randomised controlled trials showed 
probiotic therapy significantly decreased liver aminotransferases, total-cholesterol level, TNF-α and 
improve insulin resistance in NAFLD patients but did not show any changes in BMI, glucose or LDL 
levels [136]. Of the four RCTs included in this meta-analysis, the studied probiotics included 
lactobacillus, bifidobacterium and streptococcus [136].  Further data, including histological studies 
are needed with probiotics. A recent double blind randomised controlled trial looking at effect of 
VSL#3 in obese children with biopsy-proven NAFLD [137] concluded there was an improvement in 
the USS appearances of the liver although there was no difference in TG levels, HOMA scores and 
serum ALT levels.  A study which tried to evaluate the effects of Bifidobacterium longum with 
fructo-oligosaccharides (Fos) with lifestyle modification vs lifestyle modification alone in the 
treatment of NASH in adults [138] showed that the treated group demonstrated a significant 
improvement in serum AST levels, reduction of TNF-α, CRP, HOMA-IR, serum endotoxin, steatosis, 
and the NASH activity index [138].  
Liver transplantation 
For those patients with end-stage liver disease due to NAFLD, liver transplantation (LT) is the only 
definitive treatment [139]. Outcomes post-transplant for such patient are comparable to that seen with 
other indications, although this likely reflects stringent case selection. Recurrence of NASH is 
common post-transplant due to the presence of existing metabolic risk factors as well as the use of 
immunosuppression such as corticosteroid, although it rarely results in allograft loss.  
Conclusion 
The incidence of NAFLD is increasing rapidly due to rising rates of obesity in both children and 
adults, and can vary from simple steatosis to inflammation all the way through to fibrosis and 
cirrhosis. Hepatic steatosis is recognised to be the consequence of a complex interplay between diet, 
environment and the liver and adipose tissues, although a full understanding of its pathogenesis has 
not yet been elucidated [4]. The presence of fibrosis is important in the prognosis of the disease since 
it confers an increased overall mortality from cardiovascular, liver, and also malignancy. Whilst there 
are no licensed drug therapies at present, there are many late phase clinical trials in progress so this 
will likely change in the near future. Given that cardiovascular disease accounts for the majority of 
deaths in NAFLD, the challenge will be managing these two components simultaneously.  
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Figure legends: 
 
Figure 1: Clinical progression of non-alcoholic fatty liver disease 
 
Figure 2: Pathogenesis of non-alcoholic fatty liver disease 
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Table 1: Summary of treatments studied for patients with Non-alcoholic fatty liver disease 
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Highlights for review 
 Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic 
syndrome and an independent risk factor for cardiovascular disease irrespective of 
other risk factors such as age, gender, obesity, diabetes mellitus and 
dyslipidaemia. 
 
 NAFLD is considered to be complex and multifactorial disease phenotype as a 
result of environmental factors action on an individual with susceptible polygenic 
background.  
 
 NAFLD ranges from simple steatosis (SS), steatohepatitis (SH), fibrosis, cirrhosis 
to hepatocellular carcinoma. Unfortunately, the mechanism behind the progression 
from SS to SH was not fully understood.  
 
 The underlying mechanism for NAFLD pathogenesis is complex, however insulin 
resistance, accumulation of triglycerides and free fatty acids are thought to play an 
essential role in the pathogenesis.   
 
 The mainstay of management is lifestyle modification and in addition, other 
underlying metabolic risk factors should be addressed and managed effectively.  
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